ABSTRACT
Cytotoxic chemotherapeutic agents play an integral part in the management of patients with gynecologic malignancies, particularly in those with ovarian cancer. Although there are many potential benefits of treatment, there can also be significant toxicity that may adversely impact on patients’ quality of life. Furthermore, toxicity of therapy may result in treatment delays, dose reductions, and even cessation of treatment, which could adversely affect outcome. This chapter describes the role of supportive treatments in themanagement of gynecologicmalignancy, with indications and guidelines for usage of these therapeutic modalities.
